Kornimate/medical-research-clean huggingface dataset:
resistance training and amino pyridine in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: prolonged-release fampridine (sr-fampridine) can improving walking capacity in approximately 40% of ms patients suffering from this by overcoming partly or total conduction block due to demyelination. resistance training has been shown to provide the same kind of benefits for patients by targeting the muscular component of the motor unit. thus by combining the two it is likely to see an synergistic effect. this trial is designed as a double blind, randomized placebo controlled trial with subsequent cross-over. participants in the two arms will go through the same progressive training program targets at the lower limbs. for 24 weeks one group receives sr-fampridine and the other receives placebo. in the the end there is another four weeks of training after cross-over has been performed.

see above

Eligibility criteria:
inclusion criteria: * patients with relapsing remitting multiple sclerosis (rrms), secondary progressive multiple sclerosis (spms) or primary progressive multiple sclerosis (ppms) fulfilling the mcdonald criteria * expandend disability status scale (edss) 3-6.5 * pyramidal functional score ≥ 2 * participants must be able to transport self to gym and to the university of southern denmark * participants must be able to complete t25fw and ssst * fertile female participants are obliged to use hormonal contraceptive measures exclusion criteria: * history of epileptic seizures * ms relapse or change in disease modifying treatment (dmt) within 60 days * cancer within five years * blood pressure ≥ 160/100 * severe arrhythmia or ischaemic heart disease or unexplained abnormal cardiac auscultation * ≥ alt 90 u/l, ≥ bsp 210 u/l, ≥ γ-gt 230 u/l * gfr \< 80 ml/min. * history of severe pulmonary disease or unexplained abnormal pulmonary auscultation * pregnancy * breastfeeding * allergy to substances contained in prolonged release fampridine tablets * concomitant treatment with carvedilol, propranolol or metformin.
feasibility and acceptability of risk stratification in the fourth trimester to reduce maternal morbidity and mortality

Conditions: Hypertensive Disorder of Pregnancy

Summary: hypertensive disorders of pregnancy (hdp) are major causes of maternal morbidity and mortality globally and are associated with peripartum and future cardiovascular disease, including stroke, heart failure, and myocardial infarction. about 1 out of every 10 maternal deaths in sub-saharan africa are associated with hdp, and most of these deaths are preventable with timely, implementation of evidence-based strategies, including postpartum blood pressure (bp) monitoring, treatment of elevated bp and comprehensive postpartum follow up as recommended by the american college of obstetricians and gynecologists (acog) and the world health organization (who). this study aims to contextualize, implement, and evaluate the feasibility, fidelity, and acceptability of: 1) postpartum remote blood pressure monitoring and 2) ntprobnp testing for postpartum risk stratification in women with hdp at the university of abuja teaching hospital in the federal capital territory of nigeria

aims: 1. to evaluate the feasibility, fidelity, and acceptability of home blood pressure monitoring in postpartum patients (n=90) with hdp. the investigators hypothesize that remote blood pressure monitoring will be feasible, implemented as intended, and acceptable among patients, physicians, and other health care workers to improve awareness and early diagnosis of elevated blood pressures (\>140/90 mm hg) in postpartum patients with hdp. 2. to evaluate the association between n terminal-probnp (nt-probnp) levels and short-term cardiovascular outcomes (i.e., all-cause cardiovascular hospital readmission, postpartum pre-eclampsia, hypertensive urgency/emergency, stroke, heart failure/pulmonary edema, seizure and mortality at 12-weeks postpartum) in patients with hdp.

Eligibility criteria:
inclusion criteria: * adults \>18 years of age * admitted for delivery * clinical diagnosis of hdp (i.e., chronic hypertension, gestational hypertension, preeclampsia, eclampsia, the hellp syndrome, or chronic hypertension with superimposed preeclampsia) control participants: * adults \>18 years of age * admitted for delivery * with an uncomplicated pregnancy and delivery exclusion criteria: * unable to provide consent * unable to check blood pressure at home
effects of abatacept on the progression to rheumatoid arthritis(palaba study)

Conditions: Palindromic Rheumatism, Wrist

Summary: the main objective of this trial is to test the hypothesis that abatacept can reduce the progression of rheumatoid arthritis in acpa+ or rf+ patients with palindromic rheumatism compared with patients treated with hydroxychloroquine.

the main objective of this trial is to test the hypothesis that abatacept can reduce the progression of rheumatoid arthritis in acpa+ or rf+ patients with palindromic rheumatism compared with patients treated with hydroxychloroquine.

Eligibility criteria:
inclusion criteria: * patients with pr according to guerne and weissman modified criteria (18) and with: * disease evolution \> 3 months and \< 24 months. * acpa positivity proven by elisa test or chemiluminescence (ccp2) and/or rheumatoid factor positivity (elisa, nephelometry or chemiluminescence). * greater than 18 years of age. exclusion criteria: * persistent arthritis: (involvement in one or more joints \> 1 week). * criteria of other rheumatic diseases (ra, sle, etc.). * evidence of radiographic damage (join erosions). * absence of acpa or rf. * contraindication or intolerance to study drugs (abatacept or hydroxychloroquine). * steroid treatment one month before study entry. * previous antitrheumatic therapy with synthetic dmards (methotrexate, leflunomide, sulfasalazine, cyclosporine, antimalarials.) or biological dmards. * pregnant women or who want to be pregnant during the study.
confirmatory clinical trial for verifying the efficacy and safety of 'alzguard' as a digital dementia diagnostic aid-tool for the diagnosis of the major neurocognitive disorders

Conditions: Dementia; Major Neurocognitive Disorder

Summary: the goal of this clinical trial is to evalute the efficacy of alzguard, a smartphone-based digital therapeutic(dtx), in comparison to diagnosis by medical doctors, as weel as to assess the safety of the application.

the study will be conducted across multiple sites, enrolling participants aged 55 to 85 years olds. the primary objective of the study is to compare the diagnositic accuracy of alzgaurd against traditional diagnostic evaluactions conducted by medical professionals. the primary endpoint for efficacy will be the area under the curve(auc), which will measure the diagnostic performance of the application. this statistical metric will help determine how well alzguard can identify dementia compared to standard diagnostic methods.

Eligibility criteria:
inclusion criteria: * participants must be between 55 and 85 years old (both men and women). * participants must be able to understand and voluntarily agree to the purpose, content, and procedures of the clinical trial. exclusion criteria: * participants with no literacy or illiteracy. * participants with an intellectual disability. * participants with presenting active psychiatric symptoms. * participants who have difficulty alzguard application * participants who are unable to use a smartphone, unless they can use it with assistant. * participants with a history of suicidal ideation or suicidal complusion in the last 6 months. * other conditions as deemed inappropriate for study participant by the principal investigator(pi).
impact of oropharyngeal administration of colostrum in the first 48 hours of life term premature newborn ≤ 32 weeks of amenorrhea

Conditions: Infant, Premature

Summary: colostrum is the first milk secreted by the mother when the tight junctions of mammary epithelium open, allowing the cellular transport of a multitude of components and immunological protective derivatives of the maternal circulation to the milk, and especially immunoglobulins a type. colostrum is not given to preterm neonates. the assumption behind this work is that the oro pharyngeal administration of colostrum early in preterm infants could help deliver an oral immunotherapy even before the installation of enteral nutrition, through interactions with lymphoid tissues of the oropharynx and the gastrointestinal tract. this practice would improve the digestive tolerance and the establishment of enteral feeding, the decrease in mucosal inflammatory phenomena, but also to provide any protection against subsequent infections. finally, there could be an improvement in the secondary immune tolerance with a decrease in the occurrence of allergic phenomena.


Eligibility criteria:
inclusion criteria: * new premature infant with a term weight ≤ 32 weeks amenorrhea at nice university hospital * mother seronegative for hiv exclusion criteria: * neonates with congenital pathologies immediate prenatal or neonatal diagnosis will not be included. * therapy of the mother incompatible with breastfeeding during pregnancy
rw study of adjuvant radiotherapy in locally advanced thyroid cancer

Conditions: Thyroid Cancer

Summary: this study is a real-world study to observe the role of adjuvant radiotherapy in locally advanced recurrent high-risk thyroid cancer. the study included thyroid cancer that requires adjuvant radiotherapy to increase local control rate, excluding undifferentiated cancer. local-regional recurrence free survival is the primary endpoint of the study.


Eligibility criteria:
inclusion criteria: * patients voluntarily join this study and sign an informed consent form; * age: ≥ 14 years old,\<80 years old, male or female not limited; * thyroid cancer diagnosed by histopathology, including differentiated thyroid cancer, medullary carcinoma, poorly differentiated carcinoma, etc; * high risk of local late recurrence, meeting any of the following criteria: 1. the surgery did not achieve r0 resection; 2. after neoadjuvant therapy; 3. pathological types with poor prognosis, such as poorly differentiated cancer, castle, etc; 4. thyroid cancer with obvious extracapsular invasion, invading important structures such as the esophagus, trachea, and recurrent laryngeal nerve, requiring adjuvant radiotherapy; 5. for patients with distant metastasis, researchers need to determine the value of local treatment; * the main organ functions are normal; * good compliance and cooperation with follow-up. exclusion criteria: * untreated thyroid cancer or thyroid cancer that has only undergone surgical biopsy; * within 5 years or simultaneously suffering from other active malignant tumors. cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group; * previously received radiation therapy for the head and neck area; * pregnant or lactating women; * there are other physical illnesses that affect patients' ability to receive standard treatment; * according to the researcher's judgment, there may be other factors that could force the subject to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of trial data; * individuals with claustrophobia who are unable to undergo radiation therapy; * other patients deemed unsuitable for inclusion by the treating physician.
study of re-operation rate after introduction of evidence based algorithm for the treatment of ankle fractures

Conditions: Ankle Fractures; Surgery; Syndesmotic Injuries; Posterior Malleolus Fractures

Summary: there is a high incidence of re-operations after surgery for ankle fractures. according to the danish fracture database (dfdb) the re-operation rate, excluding hardware removal, is almost 10%. we are conducting a study on the efficacy of an evidence based algorithm for the treatment of ankle fractures.

treatment of ankle fractures is complex and includes assessment of fracture pattern, severity of soft-tissue involvement and general health- and functional status of the patients. historically most fractures, undisplaced as well as displaced, were treated non-operatively with acceptable results but in recent years there is an increasing trend towards operative management of unstable fractures. techniques for operative management of ankle fractures are varied and assessment of instability is mainly based on classic x-ray classification systems such as lauge-hansen or the ao that are difficult to reproduce\[6\]. we hypothesize that a standardized and evidence based approach to ankle fracture management will lead to a decrease in re-operation rate. the aim of this study is to standardize the management of ankle fractures in our department, by introducing an algorithm based on best evidence present. we want to investigate: 1. the effect of this algorithm on the re-operation rate of surgically treated ankle fractures in a two-year prospective observational setup with a minimum of one-year of follow-up. 2. the need for surgery and functional outcome of patients with isolated lateral malleolus fractures in which the treatment is dictated by ankle stability assessed on weight bearing radiographs.

Eligibility criteria:
inclusion criteria: * all patients treated for ankle fractures at our institution during the study period are asked to participate in the study. exclusion criteria: * not speaking danish not followed up at our institution not mentally capable of filling out questionnaire
pharmacist-driven stress ulcer prophylaxis minimization in the intensive care unit

Conditions: Stress Ulcer

Summary: pharmacologic stress ulcer prophylaxis is routinely used in the intensive care unit (icu) to prevent upper gastrointestinal (gi) bleeding in critically ill patients.

historically, the two independent risk factors for stress-related gi bleeds were coagulopathy and mechanical ventilation for more than 48 hours; however, several additional risk factors have been identified, such as shock, multiple organ failure, traumatic brain injury, and major burns. acid suppressive medications such as proton pump inhibitors or histamine-2 receptor antagonists are prescribed to reduce the rate of bleeding from stress ulceration despite a lack of benefit from placebo-controlled trials. in addition to lack of proven benefit, the incidence of clinically significant stress-related gi bleeding has decreased over time, likely due to improvements in critical care and earlier enteral feeding.

Eligibility criteria:
inclusion criteria: * patients ≥18 years icu location status exclusion criteria: * if patient has one of the following: * coagulopathy (defined as: platelets \ 1.5, or partial thromboplastin time \> 2 times the control value) * mechanical ventilation for \> 48 hours and on \< 50% goal tube feeds * shock state on vasopressors/inotropes and on \< 50% goal tube feeds (or \< 50% of diet) * on total parenteral nutrition * use of acid suppressive therapy prior to admission * admission with gi bleeding * history of peptic ulcer disease * surgery on the gi tract or cardiac surgery during the current hospital admission * pregnancy * h. pylori infection treatment * hypersecretory disorder (ex: zollinger-ellison) * known erosive esophagitis/gastritis (not heartburn or gastroesophageal reflux disease) * traumatic brain injury with glasgow coma scale score ≤ 10 * major burn (˃30% body surface area) * major trauma requiring icu admission * spinal cord injury requiring icu admission if patient has two or more of the following: * administration of ˃ 100 mg daily of prednisolone (or equivalent) * sepsis * acute renal failure * acute hepatic failure
efficacy of dietary supplement in subjects with acid reflux and/or abdominal bloating/distention and gi symptoms

Conditions: Healthy

Summary: this study was a prospective randomized clinical study. there was interventional treatment for a total of 8 weeks including a 2-week washout period. the subjects attended four appointments in the clinic throughout the duration of the study. study primary objective: • to assess improvement in bloating symptoms study secondary objectives: * to assess safety and tolerability of the formulation * to compare the time taken for perceptual improvement in bloating/distention * enzyme blood assays * to assess quality of life indices


Eligibility criteria:
inclusion criteria: * written informed consent to participate in the study. * willingness to actively participate in the study and to come to the scheduled visits. * female and/or male * from 18 to 85 years of age * patients with self-reported abdominal bloating, abdominal distention, flatulence, and abdominal discomfort either after meals or not at least 3x a week for a minimum of the past 2 weeks exclusion criteria: * drug addicts, alcoholics. * aids, hiv-positive or infectious hepatitis * diabetes mellitus * disorders known to affect gi motility such as gastroparesis or amyloidosis. * disorders with gi symptoms such as irritable bowel syndrome, inflammatory bowel disease and celiac disease * history of surgery known to alter the normal function of the gi tract. * conditions which exclude participation or might influence the test reaction/evaluation. * participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area. * cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years. * documented allergies to cosmetic products and/or ingredients * systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) within the last 6 weeks prior to the start of the study and/or throughout the entire course of the study. * oral steroids within the last 4 weeks prior to the start of the study and/or throughout the entire course of the study * oral or systemic therapy with antibiotics within the last 3 months prior to the start of the study and/or throughout the entire course of the study * subjects who were treated with biologics within the last 6 months prior to the start of the study and/or throughout the entire course of the study. * one of the following illnesses if not medicated: cardiovascular diseases, thyroid hyperfunction, asthma, hypertension.
influence of trauma on pain area and widespreadness in chronic pain patients

Conditions: Chronic Pain; Trauma

Summary: it is well known that patients suffering from chronic pain report higher levels of pain, anxiety, and depression if they have experienced a traumatic event. however, little is know about pain area and widespreadness. in this retrospective study, we want to investigate whether pain area and widespreadness differs in chronic pain patients with and without traumatic events. to test this hypothesis we will retrospectively analyse pain drawings collected at the pain outpatient department from hannover medical school. participants will be divided into four groups depending on the severity of their traumatic events: no trauma; accidental trauma; interpersonal trauma; post-traumatic stress disorder (ptsd).


Eligibility criteria:
inclusion criteria: * chronic pain exclusion criteria: * none
fasting predictors of ogtt and mmtt response

Conditions: Prediabetes; Hypertension; Obesity; Cardiovascular Disease

Summary: 1. to develop a database containing matched information from dynamic tests of postprandial glycemic control (ogtt or mmtt), results of a broad panel of fasting biomarkers, and clinical information related to diabetes risk obtain through subject interview. 2. to use the database to identify fasting biomarkers and associated algorithms to best predict parameters derived from dynamic tests (ogtt or mmtt) such as insulin glucose tolerance (igt), impaired first phase insulin response, etc., controlling for clinical information such as current medication use.


Eligibility criteria:
inclusion criteria: * weight \>95 exclusion criteria: * prior diagnosis of diabetes
development of a new patient reported outcome measure (prom) to assess patient's emotional wellbeing, and perceptions of total knee replacement surgery for the treatment of knee arthritis

Conditions: Complete Questionnaires Following TKR Surgery

Summary: development of a new patient reported outcome measure (prom) to assess patient's emotional wellbeing, and perceptions of total knee replacement surgery for the treatment of knee arthritis.

patients will complete the final developed questionnaire for quantitative analysis only (involves no administration of any medicinal products or medical devices) and is considered a low-risk project. patients will also be asked to complete the already validated eq-5d-5l and oxford knee score questionnaires at the same time as the final developed questionnaire following their total knee replacement surgery.

Eligibility criteria:
inclusion criteria: * patients aged 18 years of age or older. * patients who have undergone total knee replacement surgery with a metal implant for the treatment of end-stage knee arthritis in the last 3 months. * patients who have only undergone one total knee replacement surgery on the index knee. * patients who, in the opinion of the investigator, are able to understand this project and co-operate with the requirements of participation. * patients who are able to give voluntary, written informed consent to participate in this project and from whom consent has been obtained. exclusion criteria: * patients, who in the opinion of the investigator, exhibit evidence of any condition or co-morbidity that would compromise their participation in the project. * patients who are unable to understand and communicate fluently in english. * patients who have experienced a complication following total knee replacement surgery requiring a further hospital admission or revision surgery to the index knee.

Keywords: tkr questionnaire
the effects of nanocurcumin on serum oxidative stress,inflammation,adiponectin and nf-kb in blood mononuclear cells in metabolic syndrome patients (nuclear factor-κb)

Conditions: Metabolic Syndrome

Summary: metabolic syndrome is a public health challenge that includes a range of conditions including abdominal obesity, dyslipidemia, hyperglycemia, and hypertension. the syndrome is associated with an increase in the risk of cardiovascular disease and death. curcumin is a very active compound obtained from turmeric root. curcumin has antioxidant and anti-inflammatory effects, and is also involved in the regulation of several signaling pathways. since curcumin powder has low bioavailability, fast metabolism and low absorption, nanomicielle curcumin will be used in this study. therefore, this study is planned to determine the effects of supplementation of nanomicielle curcumin on oxidative stress, systemic inflammation, adiponectin in serum and nf-kb in peripheral blood mononuclear cells in patients with metabolic syndrome.


Eligibility criteria:
inclusion criteria: * 25\ 40 * waist circumference \>102 cm in men or \>88 cm in women * fasting blood glucose \>100 mg/dl * triglycerides (tg) \> 150 mg/dl * high density lipoprotein cholesterol (hdl-c) \<50 in women or \<40 in men * systolic blood pressure (sbp) \>130 mmhg and diastolic blood pressure (dbp) \>85mmhg exclusion criteria: * insulin administration for diabetes control * hypo- or hyperthyroidism, * renal failure or other chronic diseases * pregnancy and breastfeeding * taking weight loss supplements and obeying unusual weight loss plans